Shots:

• The P-III (KEYNOTE-091) trial evaluates Keytruda (200mg, IV, q3w) vs PBO in a ratio (1:1) in 1,177 patients with stage IB-IIIA NSCLC following surgical resection with/out adjuvant CT
• The trial met its 1EPs of DFS for patients with stage IB-IIIA NSCLC regardless of PD-L1 expression. In an interim analysis, the therapy showed an improvement in DFS in the all-comer population & whose tumors express PD-L1. The safety profile was consistent with previously reported studies
• The company has an extensive clinical development program in lung cancer. Keytruda is being evaluated in multiple registration-enabling studies in combination with other treatments & as monothx. for lung cancer

Ref: Businesswire | Image: Merck